RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shanghai Pharmaceuticals Holding Co Stock

Shanghai Pharmaceuticals Holding Co Equity 2024

Shanghai Pharmaceuticals Holding Co Equity

68.52 B CNY

Ticker

601607.SS

ISIN

CNE000000C82

In 2024, Shanghai Pharmaceuticals Holding Co's equity was 68.52 B CNY, a 2.18% increase from the 67.06 B CNY equity in the previous year.

Shanghai Pharmaceuticals Holding Co Aktienanalyse

What does Shanghai Pharmaceuticals Holding Co do?

Shanghai Pharmaceuticals Holding Co Ltd is a multinational corporation in the pharmaceutical industry based in Shanghai, China. The company was founded in 1994 and has been listed on the Shanghai Stock Exchange since 2007. It has become one of China's largest and most respected pharmaceutical companies over the years. The company's business model is based on the production and distribution of pharmaceutical products, particularly generics and patented medicines. The company produces and markets a wide range of drugs for the treatment of various diseases such as cancer, diabetes, and heart diseases. In addition, the company has achieved a strong position in the research and development of new drugs and has an extensive infrastructure for the production of drugs and biotechnology products. The company consists of various divisions, including the Shanghai Pharma Group, Shanghai Pharmaceuticals (USA) Inc., Shanghai Pharma Healthcare Co. Ltd., and Shanghai Pharma Biotech Co. Ltd. These companies cover a wide range of activities, including research and development, production and distribution, as well as marketing and customer service. The Shanghai Pharma Group includes various business areas such as chemicals and materials, biotechnology, distribution and retail, as well as medical devices and services. Shanghai Pharmaceuticals (USA) Inc. offers high-quality generics, while Shanghai Pharma Healthcare Co. Ltd. focuses on the online sale of medicines. Shanghai Pharma Biotech Co. Ltd. is involved in the development and marketing of biopharmaceuticals. The products offered by Shanghai Pharmaceuticals Holding Co Ltd. include a variety of drugs, dietary supplements, traditional Chinese medicines, and cosmetic products. The company has also specialized in the production of vaccines and the manufacture of active ingredients for export. In recent years, the company has made several significant acquisitions to expand its presence and influence in the global market. In 2015, it acquired Israel-based Alvogen Group, which specializes in the development and marketing of generics and biosimilar medicines. In 2016, Shanghai Pharma acquired a majority stake in China Medical System Holdings, a leading provider of innovative drugs and diagnostic products in China. Furthermore, the company has also invested in research and development to strengthen its position in the global competition. With its modern research and development facilities and strategic partnerships at home and abroad, the company aims to develop innovative drugs in vital therapeutic categories currently needed by patients. Overall, Shanghai Pharmaceuticals Holding Co Ltd offers a wide range of pharmaceutical products and services to meet the requirements and needs of patients and customers worldwide. With a focus on research and development, as well as through strategic acquisitions and partnerships, the company has strengthened its presence in the global pharmaceutical industry and positioned itself as one of the world's largest and most influential companies in this sector. Shanghai Pharmaceuticals Holding Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Shanghai Pharmaceuticals Holding Co's Equity

Shanghai Pharmaceuticals Holding Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Shanghai Pharmaceuticals Holding Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Shanghai Pharmaceuticals Holding Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Shanghai Pharmaceuticals Holding Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Shanghai Pharmaceuticals Holding Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Shanghai Pharmaceuticals Holding Co stock

What is the equity of Shanghai Pharmaceuticals Holding Co this year?

Shanghai Pharmaceuticals Holding Co has equity of 68.52 B CNY this year.

What was the equity of Shanghai Pharmaceuticals Holding Co compared to the previous year?

The equity of Shanghai Pharmaceuticals Holding Co has increased/decreased by 2.18% increased compared to the previous year.

What impact does a high equity have on investors of Shanghai Pharmaceuticals Holding Co?

A high equity is advantageous for investors of Shanghai Pharmaceuticals Holding Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Shanghai Pharmaceuticals Holding Co?

A low equity can be a risk for investors of Shanghai Pharmaceuticals Holding Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Shanghai Pharmaceuticals Holding Co affect the company?

An increase in equity of Shanghai Pharmaceuticals Holding Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Shanghai Pharmaceuticals Holding Co affect the company?

A reduction in equity of Shanghai Pharmaceuticals Holding Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Shanghai Pharmaceuticals Holding Co?

Some factors that can affect the equity of Shanghai Pharmaceuticals Holding Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Shanghai Pharmaceuticals Holding Co so important for investors?

The equity of Shanghai Pharmaceuticals Holding Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Shanghai Pharmaceuticals Holding Co take to change the equity?

To change equity, Shanghai Pharmaceuticals Holding Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Shanghai Pharmaceuticals Holding Co pay?

Over the past 12 months, Shanghai Pharmaceuticals Holding Co paid a dividend of 0.61 CNY . This corresponds to a dividend yield of about 3.07 %. For the coming 12 months, Shanghai Pharmaceuticals Holding Co is expected to pay a dividend of 0.65 CNY.

What is the dividend yield of Shanghai Pharmaceuticals Holding Co?

The current dividend yield of Shanghai Pharmaceuticals Holding Co is 3.07 %.

When does Shanghai Pharmaceuticals Holding Co pay dividends?

Shanghai Pharmaceuticals Holding Co pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Shanghai Pharmaceuticals Holding Co?

Shanghai Pharmaceuticals Holding Co paid dividends every year for the past 19 years.

What is the dividend of Shanghai Pharmaceuticals Holding Co?

For the upcoming 12 months, dividends amounting to 0.65 CNY are expected. This corresponds to a dividend yield of 3.25 %.

In which sector is Shanghai Pharmaceuticals Holding Co located?

Shanghai Pharmaceuticals Holding Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Pharmaceuticals Holding Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Pharmaceuticals Holding Co from 7/22/2024 amounting to 0.41 CNY, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did Shanghai Pharmaceuticals Holding Co pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of Shanghai Pharmaceuticals Holding Co in the year 2023?

In the year 2023, Shanghai Pharmaceuticals Holding Co distributed 0.42 CNY as dividends.

In which currency does Shanghai Pharmaceuticals Holding Co pay out the dividend?

The dividends of Shanghai Pharmaceuticals Holding Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Pharmaceuticals Holding Co

Our stock analysis for Shanghai Pharmaceuticals Holding Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Pharmaceuticals Holding Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.